Blincyto Blinatumomab 38.5 micrograms

Strengths available :  38.5 micrograms

Form :  Injection

Dosage : Induction Cycle 1-

 Days 1-28:-28 mcg/day (patient weight grater then or equal to 45kg); 15 mcg/m²/day (not to exceed 28 mcg/day)(patient weight less than 45kg).

Days 29-42:-14-day treatment-free interval (patient weight grater then or equal to 45kg);14-day treatment-free interval(patient weight less than 45kg).

 Consolidation Cycles 2-4-

Days 1-28-28 mcg/day(patient weight grater then or equal to 45kg); 15 mcg/m²/day (not to exceed 28 mcg/day)( patient weight less than 45kg).

Days 29-42-14-day treatment-free interval(patient weight grater then or equal to 45kg); 14-day treatment-free interval (patient weight less than 45kg).

Storage : Store at 2°C to 8°C

Is the medicine FDA  approved : Yes

Date of Approval : December 3, 2014

Common side effects are Agitation, bloating or swelling of the face, arms, hands, lower legs, or feet, blurred vision , chest pain, chills, confusion, cough, dizziness, fever, headache, hoarseness, irritability, lower back or side pain, painful or difficult urination, pale skin, pinpoint red , spots on the skin, rapid, shallow breathing, seeing, hearing, or feeling things that are not there, seizures, sore throat, stiff neck, tightness in the chest, tingling of the hands or feet, troubled breathing, unusual bleeding or bruising, unusual tiredness or weakness, unusual weight gain or loss, vomiting.

Pack of 1 vial of powder and 1 vial of solution